Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? [6]

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 400-402

  Berglund, A ^a   Cedermark, B ^b   Glimelius, Bengt ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; POSTMENOPAUSE; POSTOPERATIVE CARE; PRIORITY JOURNAL; THERAPY DELAY;

EID: 38849091261     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm582     Document Type: Letter

References (25)

1. Laurie JA, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447-1456.
2. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
3. Moertel CG, Fleming CG, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon cancer. A final report. Ann Intem Med 1995; 122: 321-326.
4. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-944.
5. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patents with Dukes' B versus Dukes' C colon cancer: results from four NSABP adjuvant studies. J Clin Oncol 1999; 17: 1349-1355.
6. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: Improved survival in stage II and III. Br J Cancer 2001; 85: 1437-1443.
7. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1997; 16: 295-300.
8. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-1887.
9. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. Lancet 2000; 355: 1588-1596.
10. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
11. Chau I, Norman AR, Cunningham D et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557.
12. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucavorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 2007; 25: 3456-3461.
13. Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol 2006; 17: 1347-1359.
14. Biagi JJ, Barnes C, O'Callaghan CJ. Time to adjuvant chemotherapy in colorectal cancer. Am Soc Clin Oncol Gastrointestinal Cancers Symposium 2007; (Abstr 316).
15. Czaykowski P, Gill S, Kennecke H et al. Adjuvant chemotherapy (AC) for stage 3 colon cancer: Does timing matter? Am Soc Clin Oncol Gastrointestinal Cancers Symposium 2007: (Abstr 351).
16. Ahmad I, Anan G, Alvi R et al. Impact of timing of initiation of adjuvant chemotherapy on survival after resection at colorectal cancer. Proc Am Soc Clin Oncol 2007; 25 (18 suppl): 177s.
17. Carlsson G, Albertsson P, Gustavsson B. Delayed start of adjuvant 5-FU/ leucovorin based chemotherapy in colon cancer is safe up to 12 weeks postoperatively. Proc Am Soc Clin Oncol 2007; 25 (18 suppl): 177s.
18. Gray RG, Barnwell J, Hills R et al. A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patents. Proc Am Soc Clin Oncoll 2004; (Abstr 3501).
19. Glimellus B, Dahl O, Cedermark B et al. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005; 44: 904-912.
20. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how mush? J Clin Oncol 2004; 22: 1797-1806.
21. Moertel C, Fleming T, MacDonalds J. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13: 2936-2943.
22. Chan AK, Wong A, Jenken D et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 665-677.
23. Hershman D, Hall W, Wang X et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006; 107: 2581-2588.
24. Andre T, Quinaux E, Louvet C et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732-3738.
25. Lohrisch C, Paltiel C, Gelmon K et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for earty-stage breast cancer. J Clin Oncol 2006; 24: 4888-4894.